XNCR

Xencor, Inc. [XNCR] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

XNCR Stock Summary

Top 10 Correlated ETFs

XNCR


Top 10 Correlated Stocks

XNCR


In the News

06:21 29 Mar 2024 XNCR

Xencor (XNCR) Reports Q4 Loss, Misses Revenue Estimates

Xencor (XNCR) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of $0.36. This compares to loss of $0.20 per share a year ago.

04:31 29 Mar 2024 XNCR

Xencor to Host Webcast to Review Fourth Quarter and Full Year 2023 Financial Results and Provide Vudalimab Clinical Update

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that it will report financial results for the fourth quarter and full year 2023 after the market closes on Tuesday, February 27, 2024. Xencor management will host a webcast and conference call the same day at 4:30 p.m. ET (1:30 p.m. PT) to discuss financial results, provide a.

04:41 29 Mar 2024 XNCR

Xencor (XNCR) Surges 13.4%: Is This an Indication of Further Gains?

Xencor (XNCR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

11:07 29 Mar 2024 XNCR

Xencor (XNCR) Earnings Expected to Grow: What to Know Ahead of Q4 Release

Xencor (XNCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

01:31 29 Mar 2024 XNCR

Xencor (XNCR) Upgraded to Buy: What Does It Mean for the Stock?

Xencor (XNCR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

11:56 29 Mar 2024 XNCR

Xencor: Data In Early 2024 Could Bring Shareholder Value

Xencor is expected to release data from a phase 2 study in early 2024 targeting patients with mCRPC and gynecological cancers, which could generate shareholder value. The global metastatic castration-resistant prostate cancer treatment market is expected to reach $17.71 billion by 2029. Xencor is also planning to evaluate vudalimab in combination with chemotherapy for the treatment of patients with non-small cell lung cancer; the Study is expected to start before the end of 2023.

11:02 29 Mar 2024 XNCR

Xencor: A Mid-Stage Clinical Company With Falling Losses

Xencor, Inc. is a biotech company focused on the development and commercialization of anticancer medications. They have successful partnerships and licensing agreements for approved molecules in hematologic cancers and blood disorders. Xencor's pipeline includes promising drugs like vudalimab, a bispecific antibody, but timing and toxicity concerns may impact their valuation.

09:01 29 Mar 2024 XNCR

Xencor to Present Multiple Posters at the SITC Annual Meeting

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced three poster presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), being held in San Diego, November 1-5, 2023. Poster Presentation Details Clinical Trials in Progress Abstract 764, “A Phase 1, first-in-human (FIH), open-label, dose-findin.

03:20 29 Mar 2024 XNCR

Xencor, Inc. (XNCR) Q2 2023 Earnings Call Transcript

Xencor, Inc. (NASDAQ:XNCR ) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Charles Liles - Head of Corporate Communications & IR Bassil Dahiyat - Co-Founder and CEO Nancy Valente - Chief Development Officer John Desjarlais - Chief Scientific Officer Conference Call Participants Mara Goldstein - Mizuho Securities Etzer Darout - BMO Capital Markets Edward Tenthoff - Piper Sandler Brian Chang - JPMorgan Alec Stranahan - Bank of America Merrill Lynch Kaveri Pohlman - BTIG Charles Zhu - Guggenheim Securities Matt Kemper - Leerink Partners Boris Peaker - TD Cowen Anish Nikhanj - RBC Capital Markets Operator Good afternoon, and thank you for standing by. Welcome to Xencor's Second Quarter 2023 Conference Call.

06:46 29 Mar 2024 XNCR

Xencor (XNCR) Reports Q2 Loss, Tops Revenue Estimates

Xencor (XNCR) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.91. This compares to loss of $0.57 per share a year ago.

XNCR Financial details

Company Rating
Neutral
Market Cap
1.38B
Income
-125.24M
Revenue
168.34M
Book val./share
10.99
Cash/share
9.76
Dividend
-
Dividend %
-
Employees
280
Optionable
No
Shortable
Yes
Earnings
06 May 2024
P/E
-10.56
Forward P/E
-8.41
PEG
-0.85
P/S
8.62
P/B
1.86
P/C
2.27
P/FCF
-10.42
Quick Ratio
10.36
Current Ratio
10.77
Debt / Equity
0.04
LT Debt / Equity
0.02
-
-
EPS (TTM)
-2.09
EPS next Y
-2.63
EPS next Q
-0.81
EPS this Y
123.66%
EPS next Y
25.93%
EPS next 5Y
-90.19%
EPS last 5Y
NAN%
Revenue last 5Y
1.44%
Revenue Q/Q
-24.47%
EPS Q/Q
-22.5%
-
-
-
-
SMA20
-7.91%
SMA50
9.61%
SMA100
27.13%
Inst Own
84.59%
Inst Trans
0.82%
ROA
-15%
ROE
-17%
ROC
-0.2%
Gross Margin
100%
Oper. Margin
-101%
Profit Margin
-81%
Payout
-
Shs Outstand
61.12M
Shs Float
59.5M
-
-
-
-
Target Price
56
52W Range
16.49-30.21
52W High
-26.23%
52W Low
+38.31%
RSI
47.66
Rel Volume
0.71
Avg Volume
739.31K
Volume
525.55K
Perf Week
-2.77%
Perf Month
10.1%
Perf Quarter
12.51%
Perf Half Y
10.21%
-
-
-
-
Beta
0.764
-
-
Volatility
0.44%, 1.14%
Prev Close
-1.29%
Price
22.13
Change
2.22%

XNCR Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric History 2019-12-312020-12-312021-12-312022-12-31 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
2.772.144.712.772.78
Net income per share
0.48-1.111.42-0.93-2.08
Operating cash flow per share
1.14-0.09-0.290.411.41
Free cash flow per share
0.94-0.33-0.56-0.321.06
Cash per share
9.3710.545.7210.59.81
Book value per share
10.4910.0112.5612.2611.05
Tangible book value per share
10.249.7312.2811.9510.75
Share holders equity per share
10.4910.0112.5612.2611.05
Interest debt per share
0.190.20.580.390.4
Market cap
1.94B2.5B2.34B1.55B1.28B
Enterprise value
1.9B2.34B2.23B1.55B1.31B
P/E ratio
72.34-39.2928.35-28-10.19
Price to sales ratio
12.4120.348.519.397.63
POCF ratio
30.2-498.84-138.9863.115.09
PFCF ratio
36.45-132.97-71.33-81.6720.11
P/B Ratio
3.284.363.192.121.92
PTB ratio
3.284.363.192.121.92
EV to sales
12.1519.118.129.427.81
Enterprise value over EBITDA
137.77-30.5351.01-18.8-10.34
EV to operating cash flow
29.59-468.48-132.4863.3415.44
EV to free cash flow
35.71-124.88-68-81.9720.58
Earnings yield
0.01-0.030.04-0.04-0.1
Free cash flow yield
0.03-0.01-0.01-0.010.05
Debt to equity
0.020.020.050.080.04
Debt to assets
0.020.020.040.070.03
Net debt to EBITDA
-2.861.98-2.5-0.07-0.23
Current ratio
8.395.27610.587.36
Interest coverage
0002.240
Income quality
2.40.07-0.2-0.44-0.68
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0.150.240.140.290.32
Research and developement to revenue
0.761.380.71.211.51
Intangibles to total assets
0.020.020.020.020.02
Capex to operating cash flow
-0.172.750.95-1.77-0.25
Capex to revenue
-0.07-0.11-0.06-0.26-0.13
Capex to depreciation
-2.57-2.38-2.13-4.93-1.85
Stock based compensation to revenue
0.20.260.130.30.32
Graham number
10.5915.812016.0222.77
ROIC
0.02-0.120.06-0.1-0.19
Return on tangible assets
0.04-0.090.1-0.07-0.13
Graham Net
8.38.574.478.875.17
Working capital
491.85M516.61M353.63M611.5M538.45M
Tangible asset value
578.78M556.47M717.01M709M650.47M
Net current asset value
481.36M506.87M319.66M556.57M339.6M
Invested capital
0.020.020.050.080.04
Average receivables
16.53M23.01M45.16M47.69M20.14M
Average payables
6.99M9.57M11.48M12.04M12M
Average inventory
0.50.5-18.43M-18.43M-5.64M
Days sales outstanding
51.4271.2388.0764.3124.48
Days payables outstanding
31.3619.25682.2418.47441.7
Days of inventory on hand
00-1.8K0-358.4
Receivables turnover
7.15.124.145.6814.91
Payables turnover
11.6418.960.540.870.83
Inventory turnover
118.59M0-0.28.8M-1.02
ROE
0.05-0.110.11-0.08-0.19
Capex per share
-0.2-0.24-0.27-0.73-0.35

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric History 2022-12-312023-03-312023-06-302023-09-30 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.380.320.770.980.73
Net income per share
-0.21-1.01-0.37-0.4-0.31
Operating cash flow per share
-0.43-0.51-0.64-0.452.98
Free cash flow per share
-0.62-0.7-0.73-0.512.95
Cash per share
10.879.879.298.169.76
Book value per share
12.711.4711.4411.0410.99
Tangible book value per share
12.3711.1711.1310.7310.69
Share holders equity per share
12.711.4711.4411.0410.99
Interest debt per share
0.990.980.9910.4
Market cap
1.49B1.66B1.48B1.22B1.29B
Enterprise value
1.5B1.65B1.51B1.23B1.32B
P/E ratio
-30.98-6.93-16.87-12.58-16.91
Price to sales ratio
69.0587.6232.5520.6528.91
POCF ratio
-61.08-54.27-38.79-44.787.13
PFCF ratio
-42.24-39.74-34.35-39.797.2
P/B Ratio
2.052.432.181.831.93
PTB ratio
2.052.432.181.831.93
EV to sales
69.3286.9333.0820.7829.57
Enterprise value over EBITDA
-35.17-27.77-57.92-67.31-43.47
EV to operating cash flow
-61.31-53.84-39.42-45.077.29
EV to free cash flow
-42.4-39.43-34.91-40.057.36
Earnings yield
-0.01-0.04-0.01-0.02-0.01
Free cash flow yield
-0.02-0.03-0.03-0.030.14
Debt to equity
0.080.090.090.090.04
Debt to assets
0.070.070.080.080.03
Net debt to EBITDA
-0.130.22-0.93-0.44-0.98
Current ratio
10.589.6813.310.777.36
Interest coverage
15.4970.09000
Income quality
2.030.51.741.12-9.49
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0.590.740.250.210.35
Research and developement to revenue
2.383.41.321.11.41
Intangibles to total assets
0.020.020.020.020.02
Capex to operating cash flow
0.450.370.130.13-0.01
Capex to revenue
-0.5-0.59-0.11-0.06-0.04
Capex to depreciation
-5.05-4.98-1.71-1.09-0.53
Stock based compensation to revenue
0.590.660.30.220.33
Graham number
7.7516.119.769.978.81
ROIC
-0.05-0.07-0.03-0.02-0.06
Return on tangible assets
-0.01-0.08-0.03-0.03-0.02
Graham Net
9.188.117.877.035.24
Working capital
611.5M564.92M548.93M518.14M538.45M
Tangible asset value
709M665.34M660.17M650.27M650.47M
Net current asset value
556.57M510.15M494.32M461.76M339.6M
Invested capital
0.080.090.090.090.04
Average receivables
36.94M24.43M19.94M37.51M33.15M
Average payables
12.35M12.71M14.72M14.53M14.44M
Average inventory
0.5110.50
Days sales outstanding
120.7694.2739.5883.6722.74
Days payables outstanding
420.53615.01439.77428.99387.94
Days of inventory on hand
00000
Receivables turnover
0.750.952.271.083.96
Payables turnover
0.210.150.20.210.23
Inventory turnover
2.16M2.25M2.89M00
ROE
-0.02-0.09-0.03-0.04-0.03
Capex per share
-0.19-0.19-0.08-0.06-0.03

XNCR Frequently Asked Questions

What is Xencor, Inc. stock symbol ?

Xencor, Inc. is a US stock , located in Monrovia of Ca and trading under the symbol XNCR

Is Xencor, Inc. buy or a sell ?

2 stock analysts have 2 predictions with a medium analyst target price of $56. The lowest prediction is $54 and the highest is $58

What is XNCR stock prediction ?

What is Xencor, Inc. stock quote today ?

Xencor, Inc. stock price is $22.13 today.

Is Xencor, Inc. stock public?

Yes, Xencor, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks